<DOC>
	<DOCNO>NCT02733432</DOCNO>
	<brief_summary>The purpose study determine two topical formulation CD101 safe effective treatment acute moderate severe vulvovaginal candidiasis ( VVC ) compare oral fluconazole .</brief_summary>
	<brief_title>RADIANT : CD101 v Standard Care Subjects With Acute Vaginal Yeast Infections</brief_title>
	<detailed_description>This Phase 2 , multicenter , randomize , open-label , sponsor-blind , active-controlled , dose-ranging trial female subject acute moderate severe episode vulvovaginal candidiasis . Subjects randomize 1 3 treatment arm ; CD101 gel , CD101 ointment , oral fluconazole . After randomization , subject see Day 7 ( +/-2 day ) , Day 14 ( +/- 2 day ) , &amp; Day 28 ( +/-7 day ) assess therapeutic cure safety .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Candidiasis , Vulvovaginal</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>moderate severe acute vulvovaginal candidiasis ( severity score &gt; 7 ) positive KOH wet preparation pseudohyphae bud yeast positive BD Affirm test positive vaginal culture Candida species vaginal pH &lt; 4.5 subject positive KOH wet preparation able give write informed consent receipt intravaginal systemic antifungal therapy within 7 day randomization know suspect infectious cause vulvovaginitis candidisasis history genital herpes plan treatment surgery study period cervical intraepithelial neoplasia cervical carcinoma need nonprotocol systemic vaginal antifungal therapy history hypersensitivity allergic reaction echinocandins , azoles , excipients pregnant female female breast feed woman intend become pregnant study period recent use investigational medicinal product within 28 day presence investigational device time screen subject use anticipate use intravaginal product condition Investigator believe would put subject risk participation would confound result study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>